HIV Vaccines: Adaptive Immunity and Beyond
joint with HIV Pathogenesis - Virus vs. Host
Organizer(s): Nicole Frahm, Susan W. Barnett and Galit AlterDate: March 09 - 14, 2014
Location: Fairmont Banff Springs, Banff, AB, Canada
The HIV vaccine field has undergone dramatic changes over the last several years: from the failure of the promising MRKAd5-HIV-1 vaccine to provide any protection from acquisition or disease progression to the first demonstration that an HIV vaccine can actually show efficacy with a regimen that was predicted to fail in RV144. Following these developments, the field has turned from T-cell based vaccines favored for the late nineties/early 2000s back to antibody-inducing strategies, although with a reduced focus on broadly neutralizing antibodies since these were not detected in RV144 vaccinees. This meeting aims at bringing the cellular and humoral factions together to work on a holistic approach to HIV vaccination: induction of antibodies – both binding and neutralizing – to prevent infection; a safety net of CD8 T-cell responses to control viral replication in those hosts that do become infected; and CD4 T cell help for both effector arms. In addition, we seek to provide a better understanding of the interplay of innate immune responses and the resulting adaptive response, as well as a closer look at the signals that are crucial for the induction of long-lasting memory responses. This comprehensive approach to vaccinology will be complemented by a thorough portrayal of HIV transmission, both from the viral perspective as well as the portal of entry; and by a closer look of how vaccines interact with the host’s genetic profile. Taken together, this meeting will bring scientists from all denominations together to tackle the design of a new generation of highly effective HIV vaccines.
Global Health Travel Award Deadline: October 8 2013
Scholarship Deadline: November 7 2013
Discounted Abstract Deadline: November 7 2013
Abstract Deadline: December 11 2013
Discounted Registration Deadline: January 10 2014
We gratefully acknowledge additional support for this conference from:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Novartis Vaccines and Diagnostics
We gratefully acknowledge the generous grant for this conference provided by:National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI110241-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.